<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455844</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-API-NKPL66-CT-PII</org_study_id>
    <nct_id>NCT01455844</nct_id>
  </id_info>
  <brief_title>TRIal For Efficacy of Capre on hyperTriglyceridemiA</brief_title>
  <acronym>TRIFECTA</acronym>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acasti Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JSS Medical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acasti Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether CaPre(TM), given at doses 1.0g or 2.0g for
      12 weeks, has an effect on fasting plasma triglycerides in patients with mild to high
      hypertriglyceridemia as compared to a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent (%) change in triglycerides between the baseline and the 12-week assessment visit.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in triglycerides between the baseline and the 12-week assessment visit.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">387</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>CaPre 1.0g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CaPre 2.0g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CaPre (TM)</intervention_name>
    <description>CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.</description>
    <arm_group_label>CaPre 1.0g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CaPre (TM)</intervention_name>
    <description>CaPre™ 2.0g daily for 12 weeks</description>
    <arm_group_label>CaPre 2.0g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults aged 18 to 75 years.

          -  Fasting plasma levels of TG ≥ 2.28 and &lt;10 mmol/L (200 and 877 mg/dL) on two occasions
             within 2 weeks (screening and pre-randomization visits).

          -  Patients who are currently not on pharmacotherapy for hyperlipidemia and according to
             the judgement of the physician and Canadian Guidelines for the Diagnosis and Treatment
             of Dyslipidemia initiation of drug therapy is not indicated for the duration of the
             study.

          -  Patients currently treated with statins and according to the judgement of the
             physician and the Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia
             a change in their current drug regimen is not indicated for the duration of the study.

          -  Patients treated with statin must be on stable dose for at least 6 weeks prior to
             screening.

          -  Patients are willing follow the NCEP Step 1 Diet (see Appendix 4) for the duration of
             the study.

          -  Female participants of childbearing potential (i.e. not surgically sterilized or
             post-menopausal greater than one year) must have negative serum pregnancy test and
             must be using an effective birth control method, defined as:

               1. continuous use of oral or long acting injected contraceptive for at least 2
                  months prior to study entry, or;

               2. use of an intra-uterine device or implantable contraceptive, or;

               3. use of double barrier methods of birth control

          -  Patients are at least 80% compliant with the study medication during the placebo lead
             in phase.

        Exclusion Criteria:

          -  Any concomitant medication which in the opinion of the investigator would preclude the
             patient from successfully participating in the study.

          -  Women who are pregnant or that are breast feeding.

          -  Participation in another clinical trial within 30 days from initiation of the study.

          -  Participants with a high risk for cardiovascular disease; (The definition of high-risk
             individuals will follow that of the 2009 Canadian Guidelines and include a) FRS &gt;= 20%
             10-year risk; b) All patients with uncontrolled diabetes (DCA guidelines) and c)
             Evidence of atherosclerosis -when this evidence was ascertained when clinically
             indicated);

          -  Systolic blood pressure &gt;140 mmHg and/or diastolic blood pressure &gt;90 mmHg. In
             diabetic patients, systolic blood pressure &gt; 130 mmHg and/or diastolic blood pressure
             &gt; 90 mmHg.

          -  History of stroke, intermittent claudication or transient ischemic attack.

          -  Known unstable (uncontrolled) cardiac disease , within the last 6 months.

          -  Patient with a clinically significant abnormal ECG at screening.

          -  Patients with uncontrolled diabetes mellitus, with HbA1c &gt; 7.0%.

          -  Known diagnosis of hypoglycemia.

          -  Evidence of active renal disease indicated by a fasting estimated glomerular
             filtration rate (eGFR) of &lt; 60 ml/min per 1.73 m2.

          -  Increased plasma levels (&gt;ULN) of amylase (as per respective lab upper limits) and /
             or lipase (&gt;160 IU/L) or any indication of pancreatitis pancreatitis (increased
             alcohol consumption, gallstones).

          -  History of pancreatitis.

          -  Use of any lipid lowering medication other than statins or ezetimibe(e.g niacin,
             fibrates) and/or lipid lowering NHP within 6 weeks prior to the screening visit.

          -  Intake of &gt; 2 servings per week of fish or regimented use of fish oil/omega-3
             supplements within 6 weeks prior to the screening visit.

          -  Known HIV or Hepatitis B or C positive.

          -  Patients with uncontrolled asthma as defined by the 2010 Consensus Summary of the
             Canadian Thoracic Society.

          -  Known seafood allergy or allergy to any of the medicinal or non-medicinal ingredients
             of the study medication and placebo, including:

               1. Omega-3 fatty acids (including EPA and DHA)

               2. Phospholipids (mainly phosphatidylcholine)

               3. Astaxanthin

               4. Microcrystalline cellulose

          -  Coagulopathy or on anticoagulants. Platelet aggregation inhibitors (such as aspirin or
             clopidogrel but not heparin) are permitted in the study; patients taking both aspirin
             and clopidogrel are not permitted in the study.

          -  Unable or unwilling to comply with the protocol.

          -  Patient reported weight was not stable for the past 6 months (within 3kg variation).

          -  Consumption of more than 14 standard alcoholic drinks a week.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Genest, MD, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Division, MUHC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Research</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Arts Health Research Group</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CookMed Research</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Line Medical Services Ltd</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White Hills Medical Clinic</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scisco Clinical Research</name>
      <address>
        <city>Cornwall</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corunna Medical Resarch Centre</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD-Medical Professional Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Source Unique Research Inc.</name>
      <address>
        <city>Hawkesbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagot Street Medical Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milestone Research</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPARC, Siebens-Drake Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S &amp; G Clinical Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDA Research Inc.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Medical Phoenix</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Road Diagnostic Clinic and Medical Centre</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarnia Institute of Clinical Research</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scarborough Cardiology Research</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canadian Phase Onward</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Source Unique Research Inc.</name>
      <address>
        <city>Dollard Des-Ormeaux</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLIN DE MED Grand-Mere</name>
      <address>
        <city>Grand-Mere</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Montreal Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de recherches cliniques de Montréal (IRCM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dynamik Research Inc.</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kells Medical Research</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Maladies Lipidiques de Quebec Inc</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale St-Louis</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Research Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre médical-des-carrières</name>
      <address>
        <city>St-Marc-des-carrières</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro-Recherche Inc.</name>
      <address>
        <city>St-Romuald</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

